T-Cell Receptors (TCR) and Chimeric Antigen Receptors (CAR) are the cutting edge of adoptive T-cell therapy. Both receptors deploy T-cells to target the tumor, but CAR T-cells (CAR-T) are limited to binding to cell surface antigens, while TCR T-cells (TCR-T) recognize peptides (derived from intracellular proteins) presented on the cell surface by the major histocompatibility complex (MHC) class I.
TCR-Ts have so far operated in the shadow of CAR-Ts, but may have the advantage in solid tumors. The first approved CD19-specific CAR-Ts are indicated for hematologic malignancies, but CAR-Ts were less successful against solid tumors.
This report 鈥�TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals鈥� published in May 2018 brings you up-to-date regarding key TCR-T players, key TCR-T technologies and product candidates, business models, deals and funding opportunities. The report analyzes the TCR-T pipelines and stakeholders in the field, especially focused and diversified TCR-T companies and their relationship with academia and major pharma/biotech. The report highlights the value of TCR-T assets in terms of partnering economic conditions, acquisition prices and financing rounds.
听
This report has been prepared by use of in-house databases and desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities. Sources of information are provided by scientific and non-scientific references, e.g. press releases, stock exchange disclosures, presentations, annual reports, fact sheets and patent applications (with hyperlinks leading to the source of information).
Key questions answered:
Target audience:
Table of Contents
1听听听听听听听听听 Executive Summary
2听听听听听听听听听 Introduction, Overview & Background
3听听听听听听听听听 Technologies
3.1听听听听听听 Overview & Discussion
3.1.1听听听 Technologies for Discovery of Antigens for TCRs
3.1.2听听听 Technologies for Discovery of TCRs
3.1.3听听听 Allogeneic T-Cell Technologies
3.1.4听听听 Technologies for Next Generation TCR T-Cells
3.2听听听听听听 Technologies for Discovery of Targets for TCRs
3.2.1听听听 XPRESIDENT
3.2.2听听听 Target Selection for SPEAR T-Cells
3.2.3听听听 Phosphopeptide Library
3.2.4听听听 HTS Platform for Neoantigen Identification
3.2.5听听听 pMHC Target Discovery
3.2.6听听听 EpiTarget Platform
3.2.7听听听 Neoantigen Prediction
3.3听听听听听听 Technologies for TCR Discovery
3.3.1听听听 SPEAR T-Cell Technology
3.3.2听听听 High-Throughput Identification of TUMAP-Restriced TCRs & ActEngine
3.3.3听听听 Single Cell Sequencing Platform
3.3.4听听听 TCR-GENErator
3.3.5听听听 HTS TCR Discovery and Sleeping-Beauty Expression System
3.3.6听听听 Natural, High Affinity TCRs (Bellicum)
3.3.7听听听 High-throughput cloning and characterisation of naturally selected TCRs
3.3.8听听听 Natural TCR Library
3.3.9听听听 Natural TCRs from Vaccinated Patients
3.3.10听 T-Rx Mammalian TCR Display
3.3.11听 VelociT for T-Cell Receptor Discovery
3.3.12听 Combinatorial TCR Exchange (CTE)
3.3.13听 Immune Repertoire Capture
3.3.14听 E-ALPHA Phage Display
3.3.15听 TCRL Antibodies
3.3.16听 ACTolog
3.3.17听 NEO-STIM
3.4听听听听听听 TCR Engineered Allogeneic T-Cells
3.4.1听听听 ACTallo
3.4.2听听听 universal Immune Cell Therapies (uICT)
3.4.3听听听 GammaDelta T-Cells
3.4.4听听听 Universal Donor Stem Cells
3.4.5听听听 ATO Allogeneic T-Cells
3.5听听听听听听 Next Generation Technologies to Improve Safety & Efficacy
3.5.1听听听 ARTEMIS Technology
3.5.2听听听 CID Technology Platform
3.5.3听听听 Custom Cell Engineering Technologies synNotch and Throttle
3.5.4听听听 DEACT Technology
3.5.5听听听 Dominant TCR Technology
3.5.6听听听 RetroNectin and siTCR Vector Technologies
3.5.7听听听 Stem-to-T-Cell Technology
3.5.8听听听 Transmembrane Immunomodulatory Protein (TIP) Technology
4听听听听听听听听听 Pipeline
4.1听听听听听听 Overview & Discussion
4.1.1听听听 Proof-of-concept
4.1.2听听听 Target Selection
4.1.3听听听 T-Cell Sources & Subtypes
4.1.4听听听 Use of Switches & Next Generation Constructs
4.2听听听听听听 Profiles of MAGE-A Specific TCR T-Cells
4.2.1听听听 KITE-718
4.2.2听听听 MAGE-A4c1032 T
4.2.3听听听 MAGE-A10c796 T
4.2.4听听听 TBI-1201
4.3听听听听听听 Profiles of NY-ESO-1 Specific TCR T-Cells
4.3.1听听听 GSK3377794
4.3.2听听听 NYCE T Cells
4.3.3听听听 TBI-1301
4.4听听听听听听 Profiles of AFP Specific TCR T-Cells
4.4.1听听听 AFPc332 T
4.4.2听听听 ET1402L1 CAR T-Cells
4.5听听听听听听 Profiles of PRAME Specific TCR T-Cells
4.5.1听听听 BPX-701
4.5.2听听听 MDG1011
4.5.3听听听 Dual Switch PRAME TCR T-Cells
4.6听听听听听听 Profiles of WT1 Specitic TCR T-Cells
4.6.1听听听 CMD-602
4.6.2听听听 JTCR016
4.6.3听听听 WT1-Specific Transgenic T-Cells
4.7听听听听听听 Profiles of Other Target Specific TCR T-Cells
4.7.1听听听 IMA201
4.7.2听听听 KITE-439
4.7.3听听听 LTC-H1
4.7.4听听听 TC-210
4.7.5听听听 ZI-H04
4.7.6听听听 ZI-T01
4.8听听听听听听 Profiles of Neoantigen Specific TCR T-Cells
4.8.1听听听 IMA101
4.8.2听听听 NEO-PTC-01
5听听听听听听听听听 Manufacturing
6听听听听听听听听听 Companies
6.1听听听听听听 Company Overview & Discussion
6.1.1听听听 Pure Play TCR T-Cell Companies
6.1.2听听听 Diversified Companies with TCR-T Activities
6.2 听听听听听 Pure Play TCR T-Cell Companies
6.2.1听听听 Adaptimmune Therapeutics
6.2.2听听听 Gadeta
6.2.3听听听 Immatics US
6.2.4听听听 Lion TCR
6.2.5听听听 Tactiva Therapeutics
6.2.6听听听 Zelluna Immunotherapies
6.2.7听听听 TCR2 Therapeutics
6.3听听听听听听 Profiles of Diversified Companies with TCR-T Activities
6.3.1听听听 Adicet Bio
6.3.2听听听 AgenTus Therapeutics
6.3.3听听听 Bellicum Pharmaceuticals
6.3.4听听听 BioNTech
6.3.5听听听 Bluebird bio
6.3.6听听听 Cell Medica
6.3.7听听听 Eureka Therapeutics
6.3.8听听听 GlaxoSmithKline
6.3.9听听听 Intellia Therapeutics
6.3.10听 Juno, a Celgene Company
6.3.11听 Kite, a Gilead Company
6.3.12听 Medigene
6.3.13听 Neon Therapeutics
6.3.14听 Regeneron Pharmaceuticals
6.3.15听 Takara Bio
6.3.16听 TC BioPharm
6.3.17听 Tmunity Therapeutics
6.3.18听 ZIOPHARM Oncology
6.4听听听听听听 Other Companies with TCR-T Activities
6.4.1听听听 Alpine Immune Sciences
6.4.2听听听 Atreca
6.4.3听听听 ImmunoCellular Therapeutics
7听听听听听听听听听 Business Development & Financing
7.1听听听听听听 Role of academia for the TCR-T industry
7.2听听听听听听 Role of Big Pharma & Biotech for TCR-T
7.3听听听听听听 Technology In-Licensing Deals
7.4听听听听听听 Collaborative Arrangements
7.5听听听听听听 Acquisitions of Companies and Assets
7.6听听听听听听 Financing of TCR-T Companies
8听听听听听听听听听 Outlook & Perspectives
9听听听听听听听听听 References
Tables in the Text
Table 1: Overview of Corporate Technologies to Discover pMHC Targets for TCRs
Table 2: Overview of Corporate Technologies to Discover Therapeutic TCRs
Table 3: Overview of Corporate Technologies of TCR-Engineered Allogeneic T-Cells
Table 4: Overview of Corporate Technologies to Improve Safety & Efficacy of TCR T-Cells
Table 5: Overview of TCR T-Cell Constructs in Development
Table 6: Overview of Company Solutions for Manufacturing of Vector & Cells
Table 7: Overview of in-house Company Manufacturing Solutions
Table 8: Overview of Company Choices of CMO
Table 9: Overview of Company Manufacturing Collaborations with Academia/Hospitals
Table 10: Overview of TCR T-Cell Company Profiles
Table 11: Overview of Profiles of Pure Play TCR-T Companies
Table 12: Overview of Profiles of Diversified Companies with TCR-T Activities
Table 13: Adaptimmune鈥檚 Pipeline of SPEAR T-Cells
Table 14: TCR T-cell Pipeline of Lion TCR
Table 15: TCR2 Therapeutics鈥� TRuC-T Cell Pipeline
Table 16: TCR T-Cell Pipeline of Zelluna Immunotherapy
Table 17: Bellicum Pharmaceuticals鈥� Pipeline
Table 18: Cell Medica鈥檚 Pipeline
Table 19: Overview of Kite Pharma鈥檚 Access to Technologies with Focus on TCR
Table 20: NCI Programs of TCR T-Cells under CRADA with Kite
Table 21: TC BioPharm鈥檚 Pipeline of 纬未 T-cell programs
Table 22: Clinical Pipeline of Tmunity Therapeutics
Table 23: Technology Spin-Out from Academia
Table 24: Deals with Major Pharma & Biotech
Table 25: Technology In-Licensing from Pharma & Biotech
Table 26: Collaborations & Joint Ventures
Table 27: Acquisitions
Table 28: Financing Sources of Pure Play TCR-T Companies
Table 29: Financing Sources of Selected Diversified Companies with TCR-T Activities
Companies Mentioned in the Report
听
听
*If Applicable.